Drug combinations for visceral leishmaniasis

Current Opinion in Infectious Diseases

Volumn 23, Issue 6, 2010, Pages 595-602

  Olliaro, Piero L ^a,b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

drug co administration; drug combinations; visceral leishmaniasis

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ARTEMISININ; BUPARVAQUONE; GAMMA INTERFERON; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PLACEBO; POSACONAZOLE; SITAMAQUINE; STIBOGLUCONATE SODIUM; TAFENOQUINE;

AFRICA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; DRUG TREATMENT FAILURE; ENDEMIC DISEASE; GENETIC RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; MALARIA; MIXED INFECTION; MONOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; REVIEW; TREATMENT DURATION; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; COST-BENEFIT ANALYSIS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; DRUG TOXICITY; LEISHMANIASIS, VISCERAL; PAROMOMYCIN; PHOSPHORYLCHOLINE;

EID: 78349260454     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32833fca9d     Document Type: Review

References (29)

1. World Health organization (WHO). The use of antimalarial drugs. Report of a WHO informal consultation. 13-17 November 2000. WHO/CDS/RBM/2001.33. http://whqlibdoc.who.int/hq/2001/WHO-CDS-RBM-2001.33. pdf.
2. Maltezou HC. Drug resistance in visceral leishmaniasis. J Biomed Biotechnol 2010; 617521.
3. Alvar J, Croft S, Olliaro P. Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol 2006; 61:223-274.
4. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19:111-126.
5. Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010; 362:504-512.
6. Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 2007; 5:873-882.
7. Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India. Bull WHO 2005; 83:394-395.
8. Olliaro PL, Guerin PJ, Gerstl S, et al. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 2005; 5:763-774.
9. Cheeran M, Sundar S, Rijal S, et al. A review of clinical trials of treatments for visceral leishmaniasis in the Indian subcontinent (India, Bangladesh and Nepal). Trop IKA. net J 2010; 1. http://tropika.net/svc/review/ Chinnock-20100531-Review-Visceral-Leishmaniasis-Treatment-India.
10. Seifert K, Croft SL. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother 2006; 50:73-79.
11. Sundar S, Agrawal G, Rai M, et al. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 2001; 323:419-422.
12. Chunge CN, Gachihi G, Muigai R, et al. Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans R Soc Trop Med Hyg 1985; 79:715-718.
13. Di Martino L, Mantovani MP, Gradoni L, et al. Low dosage combination of meglumine antimoniate plus allopurinol as first choice treatment of infantile visceral leishmaniasis in Italy. Trans R Soc Trop Med Hyg 1990; 84:534-535;
14. Erratum in: Trans R Soc Trop Med Hyg 1990 Sep-Oct; 84:722.
15. Laguna F, Ló pez-Vé lez R, Soriano V, et al. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV. J Infect 1994; 28:255-259.
16. Badaro R, Falcoff E, Badaro FS, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 1990; 322:16-21.
17. Van Lunzen J, Kern P, Schmitz J, et al. Short term treatment of visceral leishmaniasis of the Old World with low dose interferon gamma and penta-valent antimony. Infection 1993; 21:362-366.
18. Lortholary O, Mechali D, Christiaens D, et al. Interferon-gamma associated with conventional therapy for recurrent visceral leishmaniasis in a patient with AIDS. Rev Infect Dis 1990; 12:370-371.
19. Lustig V, Kager PA, Meenhorst PL. Treatment of visceral leishmaniasis in a patient with AIDS with antimony and gamma-interferon: remission and prevention of relapse by maintenance therapy with weekly pentamidine. Neth J Med 1995; 47:66-69.
20. Kaplanski G, Buscaylet S, Penot-Ragon C, et al. Antimony/interferon-gamma combination in the treatment of visceral leishmaniasis in AIDS. AIDS 1996; 10:1172-1174.
21. Thakur CP, Olliaro P, Gothoskar S, et al. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (=paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg 1992; 86:615-616.
22. Thakur CP, Bhowmick S, Dolfi L, Olliaro P. Aminosidine plus sodium stibo-gluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial. Trans R Soc Trop Med Hyg 1995; 89:219-223.
23. Thakur CP, Kanyok TP, Pandey AK, er a¡, A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 2000; 94:429-431.
24. Melaku Y, Collin SM, Keus K, er a? Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate mono-therapy. Am J Trop Med Hyg 2007; 77:89-94.
25. Sundar S, Rai M, Chakravarty J, er a? New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008; 47:1000-1006.
26. Olliaro P, Sundar S. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. Trop Med Int Health 2009; 14:88-92.
27. Olliaro P, Darley S, Laxminarayan R, Sundar S. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India. Trop Med Int Health 2009; 14:918-925.
28. Machado-Pinto J, Pinto J, da Costa CA, er a¡, Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishma-nia) amazonensis vaccine plus antimonial. Int J Dermatol 2002; 41:73-78.
29. Ghalib H, Modabber F. Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis. Kinetoplastid Biol Dis 2007; 6:7.